Shinoda, Koji
Matsushita, Takuya
Nakamura, Yuri
Masaki, Katsuhisa
Sakai, Shiori
Nomiyama, Haruka
Togao, Osamu
Hiwatashi, Akio
Niino, Masaaki
Isobe, Noriko
Kira, Jun-ichi
Funding for this research was provided by:
Japan Society for the Promotion of Science (17K16125, 17K16125, 16H02657)
Japan Intractable Disease Research Foundation (No grant number)
Ministry of Health, Labour and Welfare (H26-Nanchitou (Nan)-Ippan-043)
Article History
Received: 13 November 2019
Accepted: 19 February 2020
First Online: 23 March 2020
Competing interests
: K.S. received speaker honoraria from Biogen Idec Japan and Takeda Pharmaceutical Company. T.M. received a grant and payment from Bayer Schering Pharma and Takeda Pharmaceutical Company for manuscript preparation and development of educational presentations and also received speaker honoraria payments from Mitsubishi Tanabe Pharma, Bayer Schering Pharma, and Biogen Idec Japan. Y.N. received grant support from Mitsubishi Tanabe Pharma, Bayer Yakuhin, Ltd., and Japan Blood Products Organization and also received speaker honoraria from Novartis Pharma. M.N. has received speaker honoraria from Biogen Idec Japan, Novartis Pharma, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, and Alexion Pharma Godo Kaisha. N.I. received grant support from Mitsubishi Tanabe Pharma, Osoegawa Neurology Clinic, Bayer Yakuhin, Ltd., and Japan Blood Products Organization. J.K. received grants from the Ministry of Health, Labour, and Welfare, Japan; the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Japan Society for the Promotion of Science; and the Japan Agency for Medical Research and Development (AMED), Japan. J.K. further received grants and personal fees from Biogen Idec Japan, Novartis Pharma, Philips and Mitsubishi Tanabe Pharma, Eisai, Otsuka Pharmaceutical, Chugai Pharmaceutical Company, Nihon Pharmaceutical Company, and Fukuda Denshi. K.M., S.S., H.N., O.T., and A.H. have nothing to declare.